| scholarly article | Q13442814 |
| P50 | author | Martine F Roussel | Q42721623 |
| Giles Robinson | Q55459192 | ||
| P2093 | author name string | Martine F Roussel | |
| Giles W Robinson | |||
| P2860 | cites work | Subgroup-specific structural variation across 1,000 medulloblastoma genomes | Q28271811 |
| beta-Catenin status predicts a favorable outcome in childhood medulloblastoma: the United Kingdom Children's Cancer Study Group Brain Tumour Committee | Q28279527 | ||
| Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome | Q28298987 | ||
| Subtypes of medulloblastoma have distinct developmental origins | Q28300616 | ||
| The genetic landscape of the childhood cancer medulloblastoma | Q28301196 | ||
| Cerebellum development and medulloblastoma | Q28304753 | ||
| Altered neural cell fates and medulloblastoma in mouse patched mutants | Q28588056 | ||
| EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations | Q29615392 | ||
| RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia | Q29617201 | ||
| Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations | Q30040534 | ||
| Gene regulation and epigenetic remodeling in murine embryonic stem cells by c-Myc | Q30886084 | ||
| Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features | Q33366431 | ||
| Isolation and characterization of c-myc, a cellular homolog of the oncogene (v-myc) of avian myelocytomatosis virus strain 29 | Q34055226 | ||
| The tumor suppressors Ink4c and p53 collaborate independently with Patched to suppress medulloblastoma formation | Q34133633 | ||
| Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas | Q34167499 | ||
| Genetic alterations in microRNAs in medulloblastomas | Q34203950 | ||
| Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations | Q34248736 | ||
| Three new types of viral oncogene of cellular origin specific for haematopoietic cell transformation | Q34280582 | ||
| Therapeutic strategies to inhibit MYC | Q34355349 | ||
| c- and N-myc regulate neural precursor cell fate, cell cycle, and metabolism to direct cerebellar development | Q34376588 | ||
| The PVT-1 oncogene is a Myc protein target that is overexpressed in transformed cells. | Q34628423 | ||
| Myc influences global chromatin structure. | Q34766868 | ||
| N-Myc and the cyclin-dependent kinase inhibitors p18Ink4c and p27Kip1 coordinately regulate cerebellar development | Q34830715 | ||
| The Brd4 extraterminal domain confers transcription activation independent of pTEFb by recruiting multiple proteins, including NSD3. | Q35096586 | ||
| Transcriptional profiling of the Sonic hedgehog response: a critical role for N-myc in proliferation of neuronal precursors | Q35163647 | ||
| N-myc can functionally replace c-myc in murine development, cellular growth, and differentiation | Q35195543 | ||
| An integrated approach to dissecting oncogene addiction implicates a Myb-coordinated self-renewal program as essential for leukemia maintenance | Q35237394 | ||
| Myc enforces overexpression of EZH2 in early prostatic neoplasia via transcriptional and post-transcriptional mechanisms | Q35640345 | ||
| Prognostic classification of pediatric medulloblastoma based on chromosome 17p loss, expression of MYCC and MYCN, and Wnt pathway activation | Q35696363 | ||
| An animal model of MYC-driven medulloblastoma | Q35774418 | ||
| Global gene expression profiling confirms the molecular fidelity of primary tumor-based orthotopic xenograft mouse models of medulloblastoma | Q35914511 | ||
| Distinct neural stem cell populations give rise to disparate brain tumors in response to N-MYC. | Q35989886 | ||
| Novel mutations target distinct subgroups of medulloblastoma. | Q36143877 | ||
| A statin-regulated microRNA represses human c-Myc expression and function. | Q36379501 | ||
| Small-molecule antagonists of Myc/Max dimerization inhibit Myc-induced transformation of chicken embryo fibroblasts | Q24292464 | ||
| Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc | Q24294647 | ||
| Selective inhibition of BET bromodomains | Q24301009 | ||
| Identification of c-MYC as a target of the APC pathway | Q24310637 | ||
| The essential cofactor TRRAP recruits the histone acetyltransferase hGCN5 to c-Myc | Q24554343 | ||
| Molecular subgroups of medulloblastoma: the current consensus | Q24615271 | ||
| Dissecting the genomic complexity underlying medulloblastoma | Q24621907 | ||
| The miR-17/92 polycistron is up-regulated in sonic hedgehog-driven medulloblastomas and induced by N-myc in sonic hedgehog-treated cerebellar neural precursors | Q24629817 | ||
| The PVT gene frequently amplifies with MYC in tumor cells | Q24633834 | ||
| miRiad roles for the miR-17-92 cluster in development and disease | Q24646970 | ||
| The miR-17~92 cluster collaborates with the Sonic Hedgehog pathway in medulloblastoma | Q24657463 | ||
| The 2007 WHO classification of tumours of the central nervous system | Q24685772 | ||
| MYC and the art of microRNA maintenance | Q26825457 | ||
| MYC activation is a hallmark of cancer initiation and maintenance | Q27026026 | ||
| Suppression of inflammation by a synthetic histone mimic | Q27665789 | ||
| MicroRNAs: small RNAs with a big role in gene regulation | Q27860896 | ||
| N-myc is essential during neurogenesis for the rapid expansion of progenitor cell populations and the inhibition of neuronal differentiation | Q28207748 | ||
| Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci | Q28236937 | ||
| Multiple recurrent genetic events converge on control of histone lysine methylation in medulloblastoma | Q28237604 | ||
| BET bromodomain inhibition as a therapeutic strategy to target c-Myc | Q28247024 | ||
| The role of EZH2 in tumour progression | Q28255886 | ||
| Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups | Q36460209 | ||
| Definition of Disease-Risk Stratification Groups in Childhood Medulloblastoma Using Combined Clinical, Pathologic, and Molecular Variables | Q36476670 | ||
| Aberrant patterns of H3K4 and H3K27 histone lysine methylation occur across subgroups in medulloblastoma. | Q36631618 | ||
| Medulloblastoma comprises four distinct molecular variants | Q36920479 | ||
| MYC, metabolism, cell growth, and tumorigenesis. | Q37040243 | ||
| Two tumor suppressors, p27Kip1 and patched-1, collaborate to prevent medulloblastoma | Q37087725 | ||
| N-myc alters the fate of preneoplastic cells in a mouse model of medulloblastoma | Q37111115 | ||
| Control of vertebrate development by MYC | Q37122364 | ||
| Myc's broad reach | Q37299032 | ||
| Roles for MYC in the establishment and maintenance of pluripotency | Q37340352 | ||
| Silencing of the miR-17~92 cluster family inhibits medulloblastoma progression | Q37378211 | ||
| An overview of MYC and its interactome | Q37406278 | ||
| MYC and transcription elongation. | Q37406282 | ||
| Medulloblastomics: the end of the beginning | Q37469904 | ||
| MYC regulation of cell growth through control of transcription by RNA polymerases I and III. | Q37717932 | ||
| Critical Role of c-Myc in Acute Myeloid Leukemia Involving Direct Regulation of miR-26a and Histone Methyltransferase EZH2. | Q38259629 | ||
| HD-MB03 is a novel Group 3 medulloblastoma model demonstrating sensitivity to histone deacetylase inhibitor treatment. | Q39262034 | ||
| Pleiotropic effects of miR-183~96~182 converge to regulate cell survival, proliferation and migration in medulloblastoma | Q39382947 | ||
| Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations | Q40339027 | ||
| Pleiotropic role for MYCN in medulloblastoma. | Q40461175 | ||
| The SmoA1 mouse model reveals that notch signaling is critical for the growth and survival of sonic hedgehog-induced medulloblastomas | Q40497319 | ||
| Short hairpin RNA screen reveals bromodomain proteins as novel targets in acute myeloid leukemia | Q40886213 | ||
| A mouse model of the most aggressive subgroup of human medulloblastoma | Q41484437 | ||
| MicroRNAs and cancer: short RNAs go a long way. | Q41906288 | ||
| Atoh1 inhibits neuronal differentiation and collaborates with Gli1 to generate medulloblastoma-initiating cells | Q42721585 | ||
| Patched1 deletion increases N-Myc protein stability as a mechanism of medulloblastoma initiation and progression. | Q42802882 | ||
| MicroRNA profiling in human medulloblastoma. | Q43415716 | ||
| Nmyc upregulation by sonic hedgehog signaling promotes proliferation in developing cerebellar granule neuron precursors | Q44222437 | ||
| Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial | Q45120061 | ||
| Treatment of early childhood medulloblastoma by postoperative chemotherapy alone | Q46367739 | ||
| Molecular risk stratification of medulloblastoma patients based on immunohistochemical analysis of MYC, LDHB, and CCNB1 expression | Q46507354 | ||
| Nodule formation and desmoplasia in medulloblastomas-defining the nodular/desmoplastic variant and its biological behavior | Q48227672 | ||
| Genetic alterations in mouse medulloblastomas and generation of tumors de novo from primary cerebellar granule neuron precursors | Q48239656 | ||
| Neurocognitive consequences of risk-adapted therapy for childhood medulloblastoma | Q48477520 | ||
| MicroRNA-182 promotes leptomeningeal spread of non-sonic hedgehog-medulloblastoma. | Q53201641 | ||
| The Smo/Smo model: hedgehog-induced medulloblastoma with 90% incidence and leptomeningeal spread. | Q53492300 | ||
| TP53 mutation is frequently associated with CTNNB1 mutation or MYCN amplification and is compatible with long-term survival in medulloblastoma. | Q54402731 | ||
| Wnt/Wingless pathway activation and chromosome 6 loss characterize a distinct molecular sub-group of medulloblastomas associated with a favorable prognosis. | Q55468802 | ||
| Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. | Q55469539 | ||
| P433 | issue | 11 | |
| P921 | main subject | medulloblastoma | Q1333608 |
| P577 | publication date | 2013-11-01 | |
| P1433 | published in | Cold Spring Harbor Perspectives in Medicine | Q21042440 |
| P1476 | title | Role of MYC in Medulloblastoma | |
| P478 | volume | 3 |
| Q28071574 | A Proteogenomic Approach to Understanding MYC Function in Metastatic Medulloblastoma Tumors |
| Q47726903 | A case of molecularly profiled extraneural medulloblastoma metastases in a child |
| Q27015699 | Adaptations of energy metabolism during cerebellar neurogenesis are co-opted in medulloblastoma |
| Q37406278 | An overview of MYC and its interactome |
| Q97543439 | Characterization of G-CSF receptor expression in medulloblastoma |
| Q52671034 | Combined BET bromodomain and CDK2 inhibition in MYC-driven medulloblastoma. |
| Q64069784 | Cytogenetic characterization of the malignant primitive neuroectodermal SK-PN-DW tumor cell line |
| Q40596524 | Downregulation of MYCN through PI3K Inhibition in Mouse Models of Pediatric Neural Cancer |
| Q47949067 | Epigenetic Drivers in Pediatric Medulloblastoma |
| Q38184910 | Genome recognition by MYC. |
| Q34981146 | Gli1/DNA interaction is a druggable target for Hedgehog-dependent tumors. |
| Q55022167 | Improved therapy for medulloblastoma: targeting hedgehog and PI3K-mTOR signaling pathways in combination with chemotherapy. |
| Q26738711 | In vitro models of medulloblastoma: Choosing the right tool for the job |
| Q48747552 | Inhibition of CDK4/6 by Palbociclib Significantly Extends Survival in Medulloblastoma Patient-Derived Xenograft Mouse Models. |
| Q64926502 | Leflunomide Synergizes with Gemcitabine in Growth Inhibition of PC Cells and Impairs c-Myc Signaling through PIM Kinase Targeting. |
| Q33790668 | MYC and the control of apoptosis |
| Q37406282 | MYC and transcription elongation. |
| Q38539670 | MYC in pancreatic cancer: novel mechanistic insights and their translation into therapeutic strategies |
| Q35741642 | MYCN-targeting miRNAs are predominantly downregulated during MYCN‑driven neuroblastoma tumor formation |
| Q38954656 | Medulloblastoma initiation and spread: Where neurodevelopment, microenvironment and cancer cross pathways |
| Q26750427 | Medulloblastoma stem cells: Promising targets in medulloblastoma therapy |
| Q34685896 | MicroRNA signatures as biomarkers and therapeutic target for CNS embryonal tumors: the pros and the cons |
| Q42376442 | MicroRNA-206 inhibits the viability and migration of medulloblastoma cells by targeting LIM and SH3 protein 1. |
| Q92060901 | MicroRNAs Targeting MYC Expression: Trace of Hope for Pancreatic Cancer Therapy. A Systematic Review |
| Q39195507 | Modeling and Targeting MYC Genes in Childhood Brain Tumors |
| Q35192672 | Molecular and in vivo characterization of cancer-propagating cells derived from MYCN-dependent medulloblastoma |
| Q55261643 | Mouse medulloblastoma driven by CRISPR activation of cellular Myc. |
| Q52658142 | NRL and CRX Define Photoreceptor Identity and Reveal Subgroup-Specific Dependencies in Medulloblastoma. |
| Q37201479 | Neuroblastoma and MYCN |
| Q35487317 | New basal cell carcinoma susceptibility loci |
| Q41701616 | Novel MYC-driven medulloblastoma models from multiple embryonic cerebellar cells |
| Q38745576 | ODZ1 allows glioblastoma to sustain invasiveness through a Myc-dependent transcriptional upregulation of RhoA. |
| Q38841348 | OTX2 expression contributes to proliferation and progression in Myc-amplified medulloblastoma |
| Q52723228 | Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas. |
| Q89022563 | Poliovirus Receptor (CD155) Expression in Pediatric Brain Tumors Mediates Oncolysis of Medulloblastoma and Pleomorphic Xanthoastrocytoma |
| Q50692461 | Prognostic significance of MYCN gene amplification and protein expression in primary brain tumors: Astrocytoma and meningioma. |
| Q88450978 | Prognostic value of Ki-67 index in adult medulloblastoma after accounting for molecular subgroup: a retrospective clinical and molecular analysis |
| Q35630706 | Proteomic profiling of high risk medulloblastoma reveals functional biology |
| Q92421585 | Role of MYC-miR-29-B7-H3 in Medulloblastoma Growth and Angiogenesis |
| Q37340352 | Roles for MYC in the establishment and maintenance of pluripotency |
| Q26827171 | Significance and therapeutic value of miRNAs in embryonal neural tumors |
| Q37670765 | Socializing with MYC: cell competition in development and as a model for premalignant cancer |
| Q27006010 | Synthetic lethal screens as a means to understand and treat MYC-driven cancers |
| Q48302746 | TP53 Mutation, MYCN Amplification, and Large Cell/Anaplastic Histology in Medulloblastoma |
| Q28114769 | The Interaction of Myc with Miz1 Defines Medulloblastoma Subgroup Identity |
| Q35542600 | The Phosphoinositide 3-Kinase p110α Isoform Regulates Leukemia Inhibitory Factor Receptor Expression via c-Myc and miR-125b to Promote Cell Proliferation in Medulloblastoma. |
| Q36497241 | The apical complex protein Pals1 is required to maintain cerebellar progenitor cells in a proliferative state |
| Q38945828 | The ubiquitin-proteasome system and chromosome 17 in cerebellar granule cells and medulloblastoma subgroups |
| Q89727327 | Therapeutic Application of PARP Inhibitors in Neuro-Oncology |
| Q34355349 | Therapeutic strategies to inhibit MYC |
| Q49798174 | Wnt Signaling and Its Impact on Mitochondrial and Cell Cycle Dynamics in Pluripotent Stem Cells |
| Q28546968 | c-Myc and AMPK Control Cellular Energy Levels by Cooperatively Regulating Mitochondrial Structure and Function |
Search more.